The impact of postinjection urinary tract infection on efficacy of intravesical onabotulinumtoxinA—A secondary analysis
Neurourology and Urodynamics · 2023
DOI: 10.1002/nau.25191 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Neurourology and Urodynamics, 2023. Verfasst von Marina Guirguis Hanna und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Urogynecology, Department of Obstetrics and Gynecology, Magee-Womens Hospital of UPMC, University of Pittsburgh, Pittsburgh, Pennsylvania…. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Urinary Bladder, Overactive, Urinary Incontinence, Urinary Tract Infections. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS.
Abstract (Originalsprache)
Objectives
To compare treatment response in women who did and did not develop a urinary tract infection (UTI) within 14 days after intravesical onabotulinumtoxinA injections for treatment of refractory urgency urinary incontinence (UUI).
Methods
This is a secondary analysis of women who received Onabotulinumtoxin A in the Refractory Overactive Bladder: Sacral Neuromodulation vs Botulinum Toxin Assessment (ROSETTA) Trial. Participants were grouped by presence or absence of UTI within 14 days of injection. UTI was defined as symptomatic with positive urine culture per the primary ROSETTA protocol. Our primary outcome was change from baseline in mean number of UUI episodes based on monthly 3‐day bladder diaries averaged over 6 months. We performed t tests and chi‐square/Fisher's exact for continuous and categorical variables. A p value of
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Urogynecology, Department of Obstetrics and Gynecology, Magee-Womens Hospital of UPMC, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Clinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
ORCID-Profile: Marina Guirguis Hanna
Förderung
- NCATS NIH HHS
Zitieren
APA
Guirguis Hanna, M., Bradley, M., Zyczynski, H., Wang, L., & Giugale, L. (2023). The impact of postinjection urinary tract infection on efficacy of intravesical onabotulinumtoxinA—A secondary analysis. Neurourology and Urodynamics. https://doi.org/10.1002/nau.25191
Vancouver
Guirguis Hanna M, Bradley M, Zyczynski H, Wang L, Giugale L. The impact of postinjection urinary tract infection on efficacy of intravesical onabotulinumtoxinA—A secondary analysis. Neurourology and Urodynamics. 2023. doi:10.1002/nau.25191
BibTeX
@article{GuirguisHanna2023,
author = {Guirguis Hanna, Marina and Bradley, Megan and Zyczynski, Halina and Wang, Li and Giugale, Lauren},
title = {The impact of postinjection urinary tract infection on efficacy of intravesical onabotulinumtoxinA—A secondary analysis},
journal = {Neurourology and Urodynamics},
year = {2023},
doi = {10.1002/nau.25191}
}
EUVIMED